Ulmer W T
Arzneimittelforschung. 1976;26(12):2218-21.
142 patients suffering from chronic obstructive lung disease were treated with 9-chloro-11beta,17,21-trihydroxy-16beta-methyl-pregna-4,4-diene-3,20-dione-17,21-dipropionate (beclometasone) metered aerosal. Between 3 subgroups: chronic infectious obstructive lung disease, allergic obstructive lung disease and chronic bronchitis without airway obstruction, there was no difference in the results. Three times per day three puffs of the metered aerosol can substitute about 6 mg prednisolone p.o. The systemic effects of the beclometasone therapy with metered aerosols are clearly less than those which are seen with a comparable oral dosage. Side effects are seen dose dependently as hoarseness and as relatively harmless Candida infection of the throat. For most of the patients with obstructive lung disease who are dependent on glucocorticosteroids beclometasone as metered aerosol should be given as basic therapy. In case higher dosages are necessary they should be given orally or parenterally.
142例慢性阻塞性肺疾病患者接受了9-氯-11β,17,21-三羟基-16β-甲基-孕甾-4,4-二烯-3,20-二酮-17,21-二丙酸酯(倍氯米松)定量气雾剂治疗。在3个亚组之间:慢性感染性阻塞性肺疾病、过敏性阻塞性肺疾病和无气道阻塞的慢性支气管炎,结果没有差异。每天3次,每次3喷定量气雾剂可替代约6mg口服泼尼松龙。倍氯米松定量气雾剂治疗的全身效应明显低于同等口服剂量时所见的效应。副作用呈剂量依赖性,表现为声音嘶哑和相对无害的咽喉念珠菌感染。对于大多数依赖糖皮质激素的阻塞性肺疾病患者,应给予倍氯米松定量气雾剂作为基础治疗。如果需要更高剂量,应口服或胃肠外给药。